EVAXION A/S
EVAXNASDAQTrading Snapshot
- Day Range
- $2.25 – $2.33
- 52-Week Range
- $2.03 – $6.92
- Volume (shares)
- 104,032
- Avg Volume (shares)
- —
- Shares Outstanding
- 6.3M
- Next Earnings
- 2027-03-04
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- —
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-38.92
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +497.3%
EVAXION A/S
EVAXAbout EVAXION A/S
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Evaxion A/S (EVAX) Q3 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q3 2026 Earnings Call Transcript

Evaxion announces strategy and business update and third quarter 2026 financial results
COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, provides strategy and busine

Evaxion to announce strategy and business update and third quarter 2026 financial results on November 19, 2026
COPENHAGEN, Denmark, November 18, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will provide a strategy and

Evaxion announce 2027 financial calendar
COPENHAGEN, Denmark, November 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces its financial cale

Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to its

New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data